SIGA Technologies, Inc.

NASDAQ•SIGA

CEO: Dr. Dennis E. Hruby Ph.D.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Listing Date: 1997-09-10

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Contact Information

31 East 62nd Street, New York, NY, 10065, United States

212-672-9100

www.siga.com

Market Cap

$391.71M

P/E (TTM)

16.8

14.2

Dividend Yield

11.0%

52W High

$9.62

52W Low

$4.95

52W Range

11%

Rank30Top 19.5%

5.1

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Average • 5.1 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$3.80M+0.00%

4-Quarter Trend

EPS

-$0.08+0.00%

4-Quarter Trend

FCF

-$11.30M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Income Decreased Sharply Net income for 2025 was $23.28M, a substantial decrease from $59.21M reported in the prior year period.

Total Revenues Fell Significantly Total revenues for 2025 totaled $94.57M, reflecting a significant contraction from $138.72M recorded in 2024.

Cash Position Remains Robust Cash and cash equivalents held steady at $155.0M at December 31, 2025, supporting liquidity needs for the near term.

BARDA Contract Execution Cumulative oral TPOXX® delivery value under the 19C BARDA Contract reached $450.2M as of December 31, 2025.

Risk Factors

Dependence on Government Contracts Substantial future revenue relies on U.S. Government commitment; failure to secure new contracts materially harms operations.

International Sales Dropped International sales sharply declined to $5.82M in 2025 from $23.0M in 2024, limiting diversification efforts.

EMA Mpox Authorization Review EMA CHMP referral on mpox effectiveness may recommend withdrawal, negatively impacting anticipated revenue streams.

Fixed Price Contract Exposure Fixed-price government contracts require absorbing cost overruns, potentially reducing profitability or causing material losses.

Outlook

Smallpox PEP Submission Targeted Targeting Supplemental NDA submission for oral TPOXX® smallpox PEP indication within the next twelve months based on trial results.

IV TPOXX Manufacturing Transition Actively transferring IV TPOXX® manufacturing process from Patheon to a new third-party site, requiring FDA approval.

Expanding International Sales Efforts Reacquired international promotional rights; building out internal sales organization to pursue recurring non-U.S. government sales.

Peer Comparison

Revenue (TTM)

OFIX

$822.31M

+2.9%

EBS

$742.90M

-28.8%

SNDL

$680.39M

+4.4%

Gross Margin (Latest Quarter)

CTMX

100.0%

+0.0pp

RIGL

91.5%

+7.7pp

KALV

91.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
OLMA	$1.17B	-8.5	-41.5%	1.3%
VTYX	$1.00B	-9.4	-48.1%	4.7%
KALV	$878.49M	-4.5	-282.0%	44.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-18.6%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

50%

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data